Background
Alzheimer's
disease (AD) is a neurodegenerative disorder that causes progressive
memory and cognitive decline during middle to late adult life. The AD
brain is characterized by deposition of amyloid β peptide (Aβ), which is
produced from amyloid precursor protein by β- and γ-secretase
(presenilin complex)-mediated sequential cleavage. Induced pluripotent
stem (iPS) cells potentially provide an opportunity to generate a human
cell-based model of AD that would be crucial for drug discovery as well
as for investigating mechanisms of the disease.
Methodology/Principal Findings
We
differentiated human iPS (hiPS) cells into neuronal cells expressing
the forebrain marker, Foxg1, and the neocortical markers, Cux1, Satb2,
Ctip2, and Tbr1. The iPS cell-derived neuronal cells also expressed
amyloid precursor protein, β-secretase, and γ-secretase components, and
were capable of secreting Aβ into the conditioned media. Aβ production
was inhibited by β-secretase inhibitor, γ-secretase inhibitor (GSI), and
an NSAID; however, there were different susceptibilities to all three
drugs between early and late differentiation stages. At the early
differentiation stage, GSI treatment caused a fast increase at lower
dose (Aβ surge) and drastic decline of Aβ production.
Conclusions/Significance
These
results indicate that the hiPS cell-derived neuronal cells express
functional β- and γ-secretases involved in Aβ production; however,
anti-Aβ drug screening using these hiPS cell-derived neuronal cells
requires sufficient neuronal differentiation.
No comments:
Post a Comment